Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

Science translational medicine - 9 Jun 2010

Whittaker Steven, Kirk Ruth, Hayward Robert, Zambon Alfonso, Viros Amaya, Cantarino Neus, Affolter Annette, Nourry Arnaud, Niculescu-Duvaz Dan, Springer Caroline, Marais Richard

Abstract excerpt

BRAF is a serine-threonine-specific protein kinase that is mutated in 2% of human cancers. Oncogenic BRAF is a validated therapeutic target that constitutively activates mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling, driving tumor cell prolife...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biocatalysis
Share to Cell Line

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Models, Molecular

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 20538618
DOI: 10.1126/scitranslmed.3000758

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20538618-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.PMID 20538618Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

[BRAF-Mutant Solid Tumor].Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.